Holen Sie sich die Stockscreener-App
11.78
1.64%
0.19
Handel nachbörslich:
12.36
0.58
+4.92%
Schlusskurs vom Vortag:
$11.59
Offen:
$11.46
24-Stunden-Volumen:
755.02K
Relative Volume:
1.21
Marktkapitalisierung:
$706.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-156.39M
KGV:
-3.1924
EPS:
-3.69
Netto-Cashflow:
$-123.06M
1W Leistung:
+0.86%
1M Leistung:
-8.82%
6M Leistung:
+32.96%
1J Leistung:
+2.35%
1-Tages-Spanne:
$11.33
$12.00
1-Wochen-Bereich:
$11.10
$12.17
52-Wochen-Spanne:
$7.30
$15.50
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Firmenname
Kalvista Pharmaceuticals Inc
Sektor
Branche
Telefon
(857) 999-0075
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Vergleichen Sie KALV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
11.78 | 706.46M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-12-18 | Eingeleitet | BofA Securities | Buy |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-29 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-20 | Eingeleitet | Needham | Buy |
| 2018-10-30 | Eingeleitet | Jefferies | Buy |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
FDA delays Kalvista’s sebetralstat decision due to resource constraints By Investing.com - Investing.com Nigeria
FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’ - BioPharma Dive
FDA delays Kalvista’s sebetralstat decision due to resource constraints - Investing.com
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis - BioSpace
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Pat - GuruFocus
KalVista’s oral HAE treatment shows efficacy for breakthrough attacks By Investing.com - Investing.com Canada
DRI Healthcare Notes FDA Delay for KalVista's' Sebetralstat New Drug Approval on "Resourcing" Issues - MarketScreener
Kalvista stock steady as JMP reiterates $19 target amid FDA delay - Investing.com Canada
Kalvista stock steady as JMP reiterates $19 target amid FDA delay By Investing.com - Investing.com South Africa
DRI Healthcare Trust Reports FDA Delay on KalVista’s Sebetralstat Decision - MSN
FDA won’t meet PDUFA goal date for sebetralstat - The Pharma Letter
DRI Healthcare Trust Comments on FDA Delay for KalVista Pharmaceuticals' Sebetralstat PDUFA Goal Date Due to FDA Resourcing Constraints - Weekly Voice
US FDA extends review of KalVista's swelling disorder drug due to heavy workload - Reuters
FDA Tells Drugmaker ‘Heavy Workload’ to Delay Approval Decision - Bloomberg
FDA cites ‘resource constraints' in delay of local biotech's drug approval decision - The Business Journals
KalVista (KALV) Shares Decline as FDA Delays Drug Review - GuruFocus
FDA delays decision on KalVista’s HAE treatment sebetralstat By Investing.com - Investing.com India
KalVista said FDA will not meet review date for sebetralstat (KALV) - Seeking Alpha
KalVista (KALV) Awaits FDA Decision on Sebetralstat Due to Revie - GuruFocus
Kalvista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date For Sebetralstat NDA - marketscreener.com
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints | KALV Stock News - GuruFocus
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints - Business Wire
Two Sigma Investments LP Has $114,000 Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KALV’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com
Research Analysts Issue Forecasts for KALV FY2026 Earnings - Defense World
Two Sigma Advisers LP Sells 15,500 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Bank of America Corp DE Has $932,000 Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of “Buy” from Analysts - Defense World
Transcript : KalVista Pharmaceuticals, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 08 - MarketScreener
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025 - BioSpace
KalVista Pharmaceuticals to Present New Sebetralstat Data at the - GuruFocus
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025 | KALV Stock News - GuruFocus
Ameriprise Financial Inc. Takes $452,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
ProShare Advisors LLC Purchases New Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2025 - BioSpace
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KALV Stock News - GuruFocus
BNP Paribas Financial Markets Has $53,000 Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
(KALV) Technical Pivots with Risk Controls - news.stocktradersdaily.com
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management - marketscreener.com
KalVista (KALV) Shows Promising Sebetralstat Results for Heredit - GuruFocus
KalVista (KALV) Shows Promising Sebetralstat Results for Hereditary Angioedema | KALV Stock News - GuruFocus
KalVista Pharmaceuticals Medical Congress Presentations Highligh - GuruFocus
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management | KALV Stock News - GuruFocus
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Reduces Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Deutsche Bank AG Grows Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals to Present at the Jefferies Global Heal - GuruFocus
KalVista Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - BioSpace
KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
Finanzdaten der Kalvista Pharmaceuticals Inc-Aktie (KALV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kalvista Pharmaceuticals Inc-Aktie (KALV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
May 23 '25 |
Sale |
11.31 |
2,146 |
24,272 |
113,026 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
May 23 '25 |
Sale |
11.31 |
1,926 |
21,782 |
98,189 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
May 22 '25 |
Sale |
11.88 |
2,689 |
31,933 |
110,172 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
May 22 '25 |
Sale |
11.88 |
2,317 |
27,516 |
96,990 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
May 22 '25 |
Sale |
11.88 |
9,999 |
118,743 |
306,618 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
May 19 '25 |
Sale |
11.84 |
2,600 |
30,791 |
95,557 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
May 19 '25 |
Sale |
11.84 |
3,808 |
45,097 |
293,367 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
May 19 '25 |
Sale |
11.84 |
2,776 |
32,876 |
106,611 |
| Venrock Healthcare Capital Par | 10% Owner |
Apr 09 '25 |
Buy |
9.42 |
25,000 |
235,500 |
5,303,985 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Mar 07 '25 |
Sale |
11.97 |
6,669 |
79,828 |
287,811 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):